Sign in

Martine Rothblatt

Chairperson and CEO at UNITED THERAPEUTICS
Board
Since 1996
Age
70 years
Education
Earned a Ph.D. in medical ethics from the University of London, a J.D., and an M.B.A.
Tenure
Founded the company in 1996 and has served as Chairperson and Chief Executive Officer since inception.

Also at UNITED THERAPEUTICS

JCE
James C. Edgemond
CFO and Treasurer
MB
Michael Benkowitz
President and COO
PAM
Paul A. Mahon
EVP, General Counsel, and Corporate Secretary

About

Martine Rothblatt is a pioneering entrepreneur with a unique blend of expertise in biotechnology, satellite communications, and ethics.

She founded the company in 1996 and has driven its mission to develop innovative therapies for rare diseases, serving as Chairperson and Chief Executive Officer since its inception.

Her professional journey includes groundbreaking work in xenotransplantation and global virus bio-surveillance, reflecting her commitment to transforming healthcare through innovation.

Before her foray into biotechnology, she was instrumental in establishing the satellite radio industry, laying the foundations for services like SiriusXM, and continues to contribute as an inventor with several U.S. patents, further highlighting her multifaceted career.

$UTHR Performance Under Martine Rothblatt

Past Roles

OrganizationRoleDate RangeDetails
SiriusXMFounderPre-1996Created the satellite radio company before founding UTHR.

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Base Salary $1,500,000Effective March 5, 2023Reflects a 6.0% increase over 2022 base salary.
Supplemental Executive Retirement Plan (SERP) $14,175,604Potential payment upon termination or change in control as of December 31, 2023Represents the accrued value under the SERP.
Health and Other Benefits $148,894As stipulated in the employment agreementIncludes automobile leasing, maintenance, and insurance costs.

Performance Compensation

Data from  FY 2023

Non-Equity Incentive Plan Compensation

MetricValueNotes
Base Salary$1,500,000 Used in cash incentive calculation
Cash Incentive Award Target %125%
Milestone Attainment100% Achievement of pre-established performance metrics
Financial Multiplier146% Based on financial performance
Patient Multiplier152% Based on patient-related metrics
Threshold$703,125
Target$1,875,000
Maximum$5,625,000
Earned Bonus$4,161,000 Calculated as: Base Salary × 125% × 100% × 146% × 152%
Payment SchedulePaid in March 2024 Cash incentive based on 2023 performance

Stock Options (Equity Incentive Plan Awards)

MetricValueNotes
Performance Period2023–2025 Three-year performance period
Grant DateMarch 15, 2023
Grant Date Fair Value$5,926,252 Target value of the stock options
Grant Date Stock Price$85.59 Exercise or base price
Target Number of Shares69,240
Maximum Number of Shares207,720 Maximum potential award value of $17,778,755
Vesting ScheduleCliff vest at end of period Contingent upon meeting performance criteria (average cash profits margin not disclosed)

Restricted Stock Units (RSUs) (Equity Incentive Plan Awards)

MetricValueNotes
Performance Period2023–2025 Three-year performance period
Grant DateMarch 15, 2023
Grant Date Stock Price$217.50
RSUs - Revenue Growth (Weight 25%)12,360 target / 37,080 maximum Target fair value: $5,376,600
RSUs - R&D Milestones (Weight 25%)12,360 target / 37,080 maximum Target fair value: $5,376,600
Total RSUs24,720 target / 74,160 maximum Total target grant date fair value: $10,753,200
Vesting ScheduleCliff vest at end of period Based on achievement of performance conditions